"We are pleased with the advances in the direct sales initiative," Poyhonen stated. "Since its inception earlier this year, we have established two contract manufacturing agreements, completed the hiring of our initial commercial organization, finalized supply chain and distribution services, and expanded flavor company evaluations of offerings from our Complimyx™ brand of taste modulation ingredients. Interest in the Complimyx ingredients and early feedback from the flavor companies have been very positive," Poyhonen noted.
"Senomyx anticipates that our two new sources of revenue, namely commercialization of S617 and the direct sales initiative, coupled with continuing commercialization of current products by our existing collaborators, will allow the Company to achieve profitability in 2015," said Poyhonen. "In addition, we anticipate that these three types of commercial sales will generate approximately $10 million in commercial revenues in 2014 and we are currently forecasting that commercial revenues will grow to approximately $25 million in 2015."
Commercialization Updates:Senomyx has created brand names for flavor ingredients that the Company will commercialize under its direct sales initiative. The umbrella brand for the taste modulation ingredients to be marketed by Senomyx, Complimyx™, was selected to connote the benefits of using these offerings to add value
Copyright©2012 PR Newswire.
All rights reserved